# Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

> **NCT00558103** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 163 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT00558103
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-05
- **Final completion:** 2011-12
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2013-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558103, "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00558103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*